Mark Douglas
5 Papers
4 Citations
Mark Douglas is an academic researcher. The author has contributed to research in topics: Myeloid & Immune system. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Olivier De Henau,Matthew Rausch,David W. Winkler,Luis Felipe Campesato,Cailian Liu,Daniel Hirschhorn Cymerman,Sadna Budhu,Arnab Ghosh,Melissa Pink,Jeremy Tchaicha,Mark Douglas,Thomas T. Tibbitts,Sujata Sharma,Jennifer Proctor,Nicole Kosmider,Kerry White,Howard M. Stern,John Soglia,Julian Adams,Vito J. Palombella,Karen McGovern,Jeffery L. Kutok,Jedd D. Wolchok,Jedd D. Wolchok,Taha Merghoub +24 more
TL;DR: It is demonstrated that targeting PI3Kγ with a selective inhibitor can reshape the tumour immune microenvironment and promote cytotoxic-T-cell-mediated tumour regression without targeting cancer cells directly.
793
Abstract B032: The PI3K-γ inhibitor, IPI-549, increases antitumor immunity by targeting tumor-associated myeloid cells and remodeling the immune-suppressive tumor microenvironment
Matthew Rausch,Jeremy Tchaicha,Thomas T. Tibbitts,Olivier De Henau,Sujata Sharma,Melissa Pink,Joseph Gladstone,Jennifer Proctor,Mark Douglas,Howard M. Stern,Taha Merghoub,Jedd D. Wolchok,Karen McGovern,Jeff Kutok,David W. Winkler +14 more
TL;DR: It is shown that IPI-549 treatment of tumor-bearing mice leads to a shift in tumor-associated myeloid cells from an immunosuppressive M2 phenotype to a proinflammatory M1 phenotype, characterized by reduced CD206 expression and enhanced expression of MHC class II and NOS2.
3
Pharmaceutical development of IPI-504, an Hsp90 inhibitor and clinical candidate for the treatment of cancer
James R. Porter,Julian Adams,Rebecca Ahn,Vince Ammoscato,Brendan Arsenault,Brian C. Austad,Gary Baker,Johan Sebastian Basuki,Marlene R. Booth,Matthew Campbell,Bennett Carter,Michael Curtis,Kris Depew,Mark Douglas,Jie Ge,Louis Grenier,Joseph Helble,John Henderson,Natalie Goltz,Dumitru Ionescu,Laila Kott,Jason Kropp,John Lee,Kaiming Li,Bradley Maurer,Denise Mayes,Roger H. Pak,Jason J. Piotrowski,Jennifer R. Porter,David Rusch,Geoff E. Sylvester,Steven G. Wong,James R. Wright +32 more
TL;DR: The development challenges associated with redox active molecules are significant due to the pH, oxygen, and temperature sensitivities associated with such chemotypes and the API and sterile drug product manufacturing processes thus warrant the monitoring and control of these key variables.
2
The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo
Mark Douglas,Alice R. Lim,James R. Porter,Kip A. West,Melissa Pink,Jie Ge,Andrew Wylie,Thomas T. Tibbits,Kurtis Biggs,Michael Curtis,Vito J. Palombella,Julian Adams,Christian C. Fritz,Emmanuel Normant +13 more
TL;DR: The results suggest that NQO1 activity is not a determinant of IPi-504 activity in vivo and, therefore, unlikely to become an important resistance mechanism to IPI-504 in the clinic.
Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors
Tao Liu,Somarajan J. Nair,Andre Lescarbeau,Jitendra D. Belani,Stéphane Peluso,James M. Conley,Bonnie Tillotson,Patrick O'Hearn,Sherri Smith,Kelly Slocum,Kip A. West,Joseph Helble,Mark Douglas,Adilah Bahadoor,Janid A. Ali,Karen McGovern,Christian C. Fritz,Vito J. Palombella,Wylie Andrew A,Alfredo C. Castro,Martin R. Tremblay +20 more
TL;DR: The ability of silvestrol and analogues to selectively inhibit the translation of proteins with high requirement on the translation-initiation machinery relative to simple 5'UTR was determined by a cellular reporter assay.